May 1, 1989

A prolonged-action somatostatin analog and carcinoid syndrome

Bulletin de l'Académie nationale de médecine
J A Chayvialle

Abstract

Octreotide, a long-acting somatostatin analogue, was used 22 patients with carcinoid syndrome. Administered at doses of 100 to 1,000 micrograms per day according to the clinical status, octreotide resulted in a definite reduction, sometimes complete, of diarrhoea and flushes in about 60% of the cases, and in a significant decrease of urinary output of 5 hydroxy-indol acetic acid from initial values, in 18 patients that could be tested before and during the initial phase of therapy (- 37.6 +/- 7.9%, p less than 0.02). The symptomatic improvement was maintained in 13 patients treated for 3-36 months, even when no anti-tumoral complementary procedure was performed. In 2 patients, treatment discontinuation was followed by symptomatic relapse, rapidly controlled when therapy was reintroduced. These results suggest that octreotide allows for short term and prolonged control of carcinoid syndrome in the majority of patients presenting with this condition.

  • References
  • Citations

References

  • We're still populating references for this paper, please check back later.
  • References
  • Citations

Citations

  • This paper may not have been cited yet.

Mentioned in this Paper

Carcinoid Tumor
Controlled-Release Preparations
Subcutaneous Injections
Somatostatin analog
Malignant Carcinoid Syndrome
Indol
Hydroxyindoleacetic Acid
Flushing
SST
Acetic Acid

About this Paper

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Bone Marrow Neoplasms

Bone Marrow Neoplasms are cancers that occur in the bone marrow. Discover the latest research on Bone Marrow Neoplasms here.

IGA Glomerulonephritis

IgA glomerulonephritis is a chronic form of glomerulonephritis characterized by deposits of predominantly Iimmunoglobin A in the mesangial area. Discover the latest research on IgA glomerulonephritis here.

Cryogenic Electron Microscopy

Cryogenic electron microscopy (Cryo-EM) allows the determination of biological macromolecules and their assemblies at a near-atomic resolution. Here is the latest research.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

LRRK2 & Immunity During Infection

Mutations in the LRRK2 gene are a risk-factor for developing Parkinson’s disease. However, LRRK2 has been shown to function as a central regulator of vesicular trafficking, infection, immunity, and inflammation. Here is the latest research on the role of this kinase on immunity during infection.

Antiphospholipid Syndrome

Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune, hypercoagulable state caused by the presence of antibodies directed against phospholipids.

Meningococcal Myelitis

Meningococcal myelitis is characterized by inflammation and myelin damage to the meninges and spinal cord. Discover the latest research on meningococcal myelitis here.

Alzheimer's Disease: MS4A

Variants within membrane-spanning 4-domains subfamily A (MS4A) gene cluster have recently been implicated in Alzheimer's disease by recent genome-wide association studies. Here is the latest research.